


Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

Claims 1-69. (canceled)

70. (New) A method for treating excessive osteolysis in a patient, comprising administering to said patient an effective amount of a compound of Formula I:



wherein

R is independently H, OH, alkyl, aryl, cycloalkyl, heteroaryl, alkoxy, heterocyclic and amino;

each R₁ is independently selected from the group consisting of alkyl, halo, aryl, alkoxy, haloalkyl, haloalkoxy, cycloalkyl, heteroaryl, heterocyclic, hydroxy, -C(O)-R₈, -NR₉R₁₀, -NR₉C(O)-R₁₂ and -C(O)NR₉R₁₀;

each R₂ is independently selected from the group consisting of alkyl, aryl, heteroaryl, -C(O)-R₈ and SO₂R'', where R'' is alkyl, aryl, heteroaryl, NR₉N₁₀ or alkoxy;

each R₅ is independently selected from the group consisting of hydrogen, alkyl, aryl, haloalkyl, cycloalkyl, heteroaryl, heterocyclic, hydroxy, -C(O)-R₈ and (CHR)R₁₁;

X is O or S;

p is 0-3;


q is 0-2;

r is 0-3;

R₈ is selected from the group consisting of -OH, alkyl, aryl, heteroaryl, alkoxy, cycloalkyl and heterocyclic;

R₉ and R₁₀ are independently selected from the group consisting of H, alkyl, aryl, aminoalkyl, heteroaryl, cycloalkyl and heterocyclic, or R₉ and R₁₀ together with N may form a ring, where the ring atoms are selected from the group consisting of C, N, O and S;

R₁₁ is selected from the group consisting of -OH, amino, monosubstituted amino, disubstituted amino, alkyl, aryl, heteroaryl, alkoxy, cycloalkyl and heterocyclic; R₁₂ is selected from the group consisting of alkyl, aryl, heteroaryl, alkoxy, cycloalkyl and heterocyclic; R₁₂ is selected from the group consisting of alkyl, aryl, heteroaryl, alkoxy, cycloalkyl and heterocyclic; Z is OH, O-alkyl, or -NR₃R₄, where R₃ and R₄ are independently selected from the group consisting of hydrogen, alkyl, aryl, heteroaryl, cycloalkyl, and heterocyclic, or R₃ and R₄ may combine with N to form a ring where the ring atoms are selected from the group consisting of CH₂, N, O and S or



wherein Y is independently CH₂, O, N or S,

Q is C or N;

n is independently 0-4; and

m is 0-3;


or a salt thereof,

wherein said compound or salt inhibits phosphorylation of colony stimulating factor 1 receptor (CSF1R).

71. (New) The method of claim 70, wherein R₁ is halo and p is 1.

72. (New) The method of claim 70, where Z is -NR₃R₄, wherein R₃ and R₄ form a morpholine ring.

73. (New) The method of claim 70, wherein Z is;




wherein each Y is CH₂, each n is 2, m is 0 and R₃ and R₄ form a morpholine ring.

74. (New) The method of claim 70, wherein R₂ is methyl and q is 2, wherein the methyls are bonded at the 3 and 5 positions.


75. (New) The method of claim 70, wherein R₅ is H.

76. (New) The method of any of claims 70-75, wherein r is 0.

77. (New) The method of claim 70, wherein the compound administered is selected from the group consisting of



78. (New) The method of claim 70, wherein the compound of formula I is selected from the group consisting of:



79. (New) The method of claim 70, wherein the patient has cancer that has metastasized to bone.
80. (New) The method of claim 70, wherein the patient has cancer that secretes macrophage colony stimulating factor (M-CSF).
81. (New) The method of claim 70, wherein the patient has osteoporosis.

82. (New) The method of claim 70, wherein the patient is post-menopausal.